List of aminoglycoside antibiotics

Antimicrobial Agents in the Treatment of Infectious Disease
(page 4)
(This chapter has 6 pages)
© Kenneth Todar, PhD

Protein synthesis inhibitors

Many therapeutically useful antibiotics owe their action to inhibition of some step in the complex process of protein synthesis. Their attack is always at one of the events occurring on the ribosome and never at the stage of amino acid activation or attachment to a particular tRNA. Most have an affinity or specificity for 70S (as opposed to 80S) ribosomes, and they achieve their selective toxicity in this manner. The most important antibiotics with this mode of action are the tetracyclines, chloramphenicol, the macrolides (e.g. erythromycin) and the aminoglycosides (e.g. streptomycin).

The aminoglycosides are products of Streptomyces species and are represented by streptomycin, kanamycin, tobramycin and gentamicin. These antibiotics exert their activity by binding to bacterial ribosomes and preventing the initiation of protein synthesis.

Streptomycin binds to 30S subunit of the bacterial ribosome, specifically to the S12 protein which is involved in the initiation of protein synthesis. Experimentally, streptomycin has been shown to prevent the initiation of protein synthesis by blocking the binding of initiator N-formylmethionine tRNA to the ribosome. It also prevents the normal dissociation of ribosomes into their subunits, leaving them mainly in their 70S form and preventing the formation of polysomes. The overall effect of streptomycin seems to be one of distorting the ribosome so that it no longer can carry out its normal functions. This evidently accounts for its antibacterial activity but does not explain its bactericidal effects, which distinguishes streptomycin and other aminoglycosides from most other protein synthesis inhibitors.

Streptomycin is the first aminoglycoside antibiotic to be discovered, and was the first antibiotic to be used in treatment of tuberculosis. It was discovered in 1943, in the laboratory of Selman Waksman at Rutgers University. Waksman and his laboratory discovered several antibiotics, including actinomycin, streptomycin, and neomycin. Streptomycin is derived from the bacterium, Streptomyces griseus. Streptomycin stops bacterial growth by inhibiting protein synthesis. Specifically, it binds to the 16S rRNA of the bacterial ribosome, interfering with the binding of formyl-methionyl-tRNA to the 30S subunit. This prevents initiation of protein synthesis.

Kanamycin and tobramycin have been reported to bind to the ribosomal 30S subunit and to prevent it from joining to the 50S subunit during protein synthesis. They may have a bactericidal effect because this leads to cytoplasmic accumulation of dissociated 30S subunits, which is apparently lethal to the cells.

Aminoglycosides have been used against a wide variety of bacterial infections caused by Gram-positive and Gram-negative bacteria. Streptomycin has been used extensively as a primary drug in the treatment of tuberculosis. Gentamicin is active against many strains of Gram-positive and Gram-negative bacteria, including some strains of Pseudomonas aeruginosa. Kanamycin is active at low concentrations against many Gram-positive bacteria, including penicillin-resistant staphylococci. Gentamicin and Tobramycin are mainstays for treatment of Pseudomonas infections. An unfortunate side effect of aminoglycosides has tended to restrict their usage: prolonged use is known to impair kidney function and cause damage to the auditory nerves leading to deafness.

Gentamicin is an aminoglycoside antibiotic, used mostly to treat Gram-negative infections. However, it is not used for Neisseria gonorrhoeae, Neisseria meningitidis or Legionella pneumophila infections. It is synthesized by Micromonospora, a genus of Gram-positive bacteria widely distributed in water and soil. Like all aminoglycosides, when gentamicin is given orally, it is not systemically active because it is not absorbed to any appreciable extent from the small intestine. It is useful in treatment of infections caused by Pseudomonas aeruginosa.

The tetracyclines consist of eight related antibiotics which are all natural products of Streptomyces, although some can now be produced semisynthetically or synthetically. Tetracycline, chlortetracycline and doxycycline are the best known. The tetracyclines are broad-spectrum antibiotics with a wide range of activity against both Gram-positive and Gram-negative bacteria. Pseudomonas aeruginosa is less sensitive but is generally susceptible to tetracycline concentrations that are obtainable in the bladder. The tetracyclines act by blocking the binding of aminoacyl tRNA to the A site on the ribosome. Tetracyclines inhibit protein synthesis on isolated 70S or 80S (eucaryotic) ribosomes, and in both cases, their effect is on the small ribosomal subunit. However, most bacteria possess an active transport system for tetracycline that will allow intracellular accumulation of the antibiotic at concentrations 50 times as great as that in the medium. This greatly enhances its antibacterial effectiveness and accounts for its specificity of action, since an effective concentration cannot be accumulated in animal cells. Thus a blood level of tetracycline which is harmless to animal tissues can halt protein synthesis in invading bacteria.

The tetracyclines have a remarkably low toxicity and minimal side effects when taken by animals. The combination of their broad spectrum and low toxicity has led to their overuse and misuse by the medical community and the wide-spread development of resistance has reduced their effectiveness. Nonetheless, tetracyclines still have some important uses, such as the use of doxycycline in the treatment of Lyme disease.

Some newly discovered members of the tetracycline family (e.g. chelocardin) have been shown to act by inserting into the bacterial membrane, not by inhibiting protein synthesis.


The tetracycline core structure. The tetracyclines are a large family of antibiotics that were discovered as natural products of Streptomyces bacteria beginning in the late 1940s. Tetracycline sparked the development of many chemically altered antibiotics and in doing so has proved to be one of the most important discoveries made in the field of antibiotics. It is a classic “broad-spectrum antibiotic” used to treat infections caused by Gram-positive and Gram-negative bacteria and some protozoa.


Doxycycline is a semisynthetic tetracycline developed in the 1960s. It is frequently used to treat chronic prostatitis, sinusitis, syphilis, chlamydia, pelvic inflammatory disease, acne and rosacea. In addition, it is used in the treatment and prophylaxis of anthrax and in prophylaxis against malaria. It is also effective against Yersinia pestis (the infectious agent of bubonic plague) and is prescribed for the treatment of Lyme disease, ehrlichiosis and Rocky Mountain spotted fever. Because doxycycline is one of the few medications that is effective in treating Rocky Mountain spotted fever (with the next best alternative being chloramphenicol), it is indicated even for use in children for this illness.

Chloramphenicol is a protein synthesis inhibitor that has a broad spectrum of activity but it exerts a bacteriostatic effect. It is effective against intracellular parasites such as the rickettsiae. Unfortunately, aplastic anemia develops in a small proportion (1/50,000) of patients. Chloramphenicol was originally discovered and purified from the fermentation of a Streptomyces species, but currently it is produced entirely by chemical synthesis. Chloramphenicol inhibits the bacterial enzyme peptidyl transferase, thereby preventing the growth of the polypeptide chain during protein synthesis.


Chemical structure of chloramphenicol

Chloramphenicol is entirely selective for 70S ribosomes and does not affect 80S ribosomes. Its unfortunate toxicity towards the small proportion of patients who receive it is in no way related to its effect on bacterial protein synthesis. However, since mitochondria originated from procaryotic cells and have 70S ribosomes, they are subject to inhibition by some of the protein synthesis inhibitors including chloramphenicol. This likely explains the toxicity of chloramphenicol. The eucaryotic cells most likely to be inhibited by chloramphenicol are those undergoing rapid multiplication, thereby rapidly synthesizing mitochondria. Such cells include the blood forming cells of the bone marrow, the inhibition of which could present as aplastic anemia. Chloramphenicol was once a highly prescribed antibiotic and a number of deaths from anemia occurred before its use was curtailed. Now it is seldom used in human medicine except in life-threatening situations (e.g. typhoid fever).

The macrolide family of antibiotics is characterized by structures that contain large lactone rings linked through glycoside bonds with amino sugars. The most important members of the group are erythromycin and oleandomycin. Erythromycin is active against most Gram-positive bacteria, Neisseria, Legionella and Haemophilus, but not against the Enterobacteriaceae. Macrolides inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit. Binding inhibits elongation of the protein by peptidyl transferase or prevents translocation of the ribosome or both. Macrolides are bacteriostatic for most bacteria but are cidal for a few Gram-positive bacteria.


Chemical structure of a macrolide antibiotic, erythromycin.

Azithromycin, shown above, is a subclass of macrolide antibiotics. Azithromycin is one of the world’s best-selling antibiotics. It is s derived from erythromycin, but it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring, thus making the lactone ring 15-membered. Azithromycin is used to treat certain bacterial infections, most often bacteria causing middle ear infections, tonsillitis, throat infections, laryngitis, bronchitis, pneumonia and sinusitis. It is also effective against certain sexually transmitted diseases, such as non-gonococcal urethritis and cervicitis.

Lincomycin and clindamycin are a miscellaneous group of protein synthesis inhibitors with activity similar to the macrolides. Lincomycin has activity against Gram-positive bacteria and some Gram-negative bacteria (Neisseria, H. influenzae). Clindamycin is a derivative of lincomycin with the same range of antimicrobial activity, but it is considered more effective. It is frequently used as a penicillin substitute and is effective against Gram-negative anaerobes (e.g. Bacteroides).


Clindamycin is a lincosamide antibiotic. It is usually used to treat infections with anaerobic bacteria but can also be used to treat some protozoal diseases, such as malaria. It is a common topical treatment for acne, and can be useful against some methicillin-resistant Staphylococcus aureus (MRSA) infections. The most severe common adverse effect of clindamycin is Clostridium difficile-associated diarrhea (the most frequent cause of pseudomembranous colitis). Although this side-effect occurs with almost all antibiotics, including beta-lactam antibiotics, it is classically linked to clindamycin use.

chapter continued
Previous Page

What Are Aminoglycosides?

These antibiotics are used mainly to treat serious infections in a clinical setting.

Aminoglycosides are a class of antibiotics used to treat serious infections caused by bacteria that either multiply very quickly or are difficult to treat.

Aminoglycosides are called bactericidal antibiotics because they kill bacteria directly. They accomplish this by stopping bacteria from producing proteins needed for their survival.

Because aminoglycosides are normally used to treat serious infections, they are typically administered into the veins of the body (intravenously, or IV).

However, some aminoglycosides can be taken orally, or as ear or eye drops.

Examples of aminoglycosides include:

  • Gentamicin (generic version is IV only)
  • Amikacin (IV only)
  • Tobramycin
  • Gentak and Genoptic (eye drops)
  • Kanamycin
  • Streptomycin
  • Neo-Fradin (oral)
  • Neomycin (generic version is IV only)

Warnings and Precautions

Avoid aminoglycosides if you’re allergic to them or any inactive ingredients these drugs may contain.

Also, you might want to ask your doctor about aminoglycosides if you:

  • Are allergic to sulfites (often found in certain wines and dried fruits)
  • Have kidney or hearing problems, including problems with balance and uncontrollable eye movements
  • Have a disorder affecting the nerves and muscles, like multiple sclerosis or myasthenia gravis.
  • Are 65 years of age or older
  • You have a newborn or very young baby who might be treated for a serious infection using aminoglycosides

Common Side Effects

Aminoglycosides are very powerful antibiotics, and their side effects can be severe — especially when taken by mouth or IV.

The Food and Drug Administration (FDA) has issued black-box warnings for aminoglycosides taken orally or intravenously, noting the following possible side effects:

  • Damage to the hearing structures in the ear, resulting in hearing loss
  • Damage to the inner ear, resulting in trouble maintaining balance
  • Kidney damage (noted by protein in the urine, dehydration, and low levels of magnesium)
  • Paralysis of skeletal muscles

Although side effects and their severity may vary from person to person, the higher the dose of an aminoglycoside you receive, or the longer the duration of use, the greater your risk of side effects.

Drug Interactions

Don’t take aminoglycosides by mouth or intravenously if you’re already taking:

  • Theracrys (BCG live intravesical)
  • Vistide (cidofovir)
  • Zanosar (streptozocin)

Ask your doctor about aminoglycosides if you’re already taking “water pills” known as loop diuretics, such as Lasix (furosemide) or Demadex (torsemide).

Talk to your doctor about aminoglycosides if you’re about to undergo surgery.

Certain drugs called neuromuscular blocking agents, often used to prevent patients from moving during surgery, enhance some of the side effects of aminoglycosides.

Aminoglycoside Antibiotics

Sources Used in Current Review

Article reviewed May 2015 by Jennifer M. Colby, PhD, DABCC.

Wong, G. et al. How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? BMC Infectious Diseases. 2014 14:288.

Banerjee, S., Narayanan, M., and Gould K. Monitoring aminoglycoside level. BMJ. 2012 345:e6354.

Roberts, J.A. et al. Individualized antibiotic dosing for patients who are critically ill: challenges and potential solutions. The Lancet. 2014. 14:498-509.

Clarke, W. Editor. Contemporary Practice in Clinical Chemistry. 2nd Edition, AACC Press, Washington DC.

Sources Used in Previous Reviews

(Reviewed 2010 May). Aminoglycoside Extended Interval Dosing and Monitoring in Adults. New York-Presbyterian Hospital Guideline: Medication Use Manual . Available online through http://www.cumc.columbia.edu. Accessed September 2012.

(2011 April 18). Extended Interval Aminoglycoside Monitoring and Dosing Guideline (Gentamicin/Tobramycin ONLY). Alberta Health Services, Covenant Health, Regional Laboratory Services . Available online through http://www.albertahealthservices.ca. Accessed September 2012.

Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 581.

PMC

  • Abis GS, Stockmann HB, van Egmond M, Bonjer HJ, Vandenbroucke-Grauls CM, Oosterling SJ. 2013. Selective decontamination of the digestive tract in gastrointestinal surgery: Useful in infection prevention? A systematic review. J Gastrointest Surg 17: 2172–2178.
  • Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, et al. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 54: 4636–4642.
  • Aínsa JA, Pérez E, Pelicic V, Berthet FX, Gicquel B, Martín C. 1997. Aminoglycoside 2′-N-acetyltransferase genes are universally present in mycobacteria: Characterization of the aac(2′)-Ic gene from Mycobacterium tuberculosis and the aac(2′)-Id gene from Mycobacterium smegmatis. Mol Microbiol 24: 431–441.
  • Aires JR, Köhler T, Nikaido H, Plésiat P. 1999. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 43: 2624–2628.
  • Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, et al. 2014. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 58: 4443–4451.
  • Al Sheikh YA, Marie MA, John J, Krishnappa LG, Dabwab KH. 2014. Prevalence of 16S rRNA methylase genes among β-lactamase-producing Enterobacteriaceae clinical isolates in Saudi Arabia. Libyan J Med 9: 24432.
  • American Thoracic Society; Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388–416.
  • Armstrong ES, Miller GH. 2010. Combating evolution with intelligent design: The neoglycoside ACHN-490. Curr Opin Microbiol 13: 565–573.
  • Avent ML, Rogers BA, Cheng AC, Paterson DL. 2011. Current use of aminoglycosides: Indications, pharmacokinetics and monitoring for toxicity. Intern Med J 41: 441–449.
  • Azucena E, Mobashery S. 2001. Aminoglycoside-modifying enzymes: Mechanisms of catalytic processes and inhibition. Drug Resist Updat 4: 106–117.
  • Barclay ML, Kirkpatrick CM, Begg EJ. 1999. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 36: 89–98.
  • Beauclerk AA, Cundliffe E. 1987. Sites of action of two ribosomal RNA methylases responsible for resistance to aminoglycosides. J Mol Biol 193: 661–671.
  • Bell J, Andersson P, Jones R, Turnidge J. 2010. 16S rRNA methylase containing Enterobacteriaceae in the SENTRY Asia-Pacific region frequently harbour plasmid-mediated quinolone resistance CTXM types. 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Abstract O559 Vienna, April 10–13.
  • Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, et al. 2013. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368: 524–532.
  • Benveniste R, Davies J. 1971. R-factor mediated gentamicin resistance: A new enzyme which modifies aminoglycoside antibiotics. FEBS Lett 14: 293–296.
  • Berçot B, Poirel L, Nordmann P. 2011. Updated multiplex polymerase chain reaction for detection of 16S rRNA methylases: High prevalence among NDM-1 producers. Diagn Microbiol Infect Dis 71: 442–445.
  • Bercovier H, Kafri O, Sela S. 1986. Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome. Biochem Biophys Res Commun 136: 1136–1141.
  • Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. 1976. Tobramycin: A review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 12: 166–200.
  • Brooke JS. 2012. Stenotrophomonas maltophilia: An emerging global opportunistic pathogen. Clin Microbiol Rev 25: 2–41.
  • Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. 2002. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 28: 936–942.
  • Buroni S, Pasca MR, Flannagan RS, Bazzini S, Milano A, Bertani I, Venturi V, Valvano MA, Riccardi G. 2009. Assessment of three resistance-nodulation-cell division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance. BMC Microbiol 9: 200.
  • Castanheira M, Costello SE, Jones RN, Mendes RE. 2015. Prevalence of aminoglycoside resistance genes among contemporary Gram-negative resistant isolates collected worldwide. 25th European Congress of Clinical Microbriology and Infectious Diseases (ECCMID), Abstract O011 Copenhagen, April 25–28.
  • Cattoir V, Nordmann P. 2009. Plasmid-mediated quinolone resistance in Gram-negative bacterial species: An update. Curr Med Chem 16: 1028–1046.
  • Costa Y, Galimand M, Leclercq R, Duval J, Courvalin P. 1993. Characterization of the chromosomal aac(6′)-Ii gene specific for Enterococcus faecium. Antimicrob Agents Chemother 37: 1896–1903.
  • Courvalin P. 1994. Transfer of antibiotic resistance genes between Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 38: 1447–1451.
  • Craig WA. 2011. Optimizing aminoglycoside use. Crit Care Clin 27: 107–121.
  • Craig WA, Redington J, Ebert SC. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27: 29–40.
  • Culebras E, Martínez JL. 1999. Aminoglycoside resistance mediated by the bifunctional enzyme 6′-N-aminoglycoside acetyltransferase-2″-O-aminoglycoside phosphotransferase. Front Biosci 4: D1–D8.
  • Cundliffe E. 1989. How antibiotic-producing organisms avoid suicide. Annu Rev Microbiol 43: 207–233.
  • Daneman N, Sarwar S, Fowler RA, Cuthbertson BH, Group SCS. 2013. Effect of selective decontamination on antimicrobial resistance in intensive care units: A systematic review and meta-analysis. Lancet Infect Dis 13: 328–341.
  • Davis BD. 1987. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 51: 341–350.
  • Davis BD, Chen LL, Tai PC. 1986. Misread protein creates membrane channels: An essential step in the bactericidal action of aminoglycosides. Proc Natl Acad Sci 83: 6164–6168.
  • Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. 2013. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41: 580–637.
  • Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, et al. 2001. Tularemia as a biological weapon: Medical and public health management. JAMA 285: 2763–2773.
  • Doi Y, Yokoyama K, Yamane K, Wachino J, Shibata N, Yagi T, Shibayama K, Kato H, Arakawa Y. 2004. Plasmid-mediated 16S rRNA methylase in Serratia marcescens conferring high-level resistance to aminoglycosides. Antimicrob Agents Chemother 48: 491–496.
  • Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. 2007. Back to the future: Using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45: 753–760.
  • Dzidic S, Bedeković V. 2003. Horizontal gene transfer-emerging multidrug resistance in hospital bacteria. Acta Pharmacol Sin 24: 519–526.
  • Eliopoulos GM, Eliopoulos CT. 1988. Antibiotic combinations: Should they be tested? Clin Microbiol Rev 1: 139–156.
  • Falagas ME, Siempos II, Bliziotis IA, Michalopoulos A. 2006. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: A meta-analysis of comparative trials. Crit Care 10: R123.
  • Feizabadi MM, Asadi S, Zohari M, Gharavi S, Etemadi G. 2004. Genetic characterization of high-level gentamicin-resistant strains of Enterococcus faecalis in Iran. Can J Microbiol 50: 869–872.
  • Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, López-Cerero L, Pascual A, Natera C, Rodríguez M, Salcedo I, Rodríguez-López F, et al. 2015. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 70: 905–913.
  • Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. 2007. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367–416.
  • Hancock RE. 1984. Alterations in outer membrane permeability. Annu Rev Microbiol 38: 237–264.
  • Hancock RE, Raffle VJ, Nicas TI. 1981. Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 19: 777–785.
  • Hancock RE, Farmer SW, Li ZS, Poole K. 1991. Interaction of aminoglycosides with the outer membranes and purified lipopolysaccharide and OmpF porin of Escherichia coli. Antimicrob Agents Chemother 35: 1309–1314.
  • Ho YI, Chan CY, Cheng AF. 1997. In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria. J Antimicrob Chemother 40: 27–32.
  • Hocquet D, Vogne C, El Garch F, Vejux A, Gotoh N, Lee A, Lomovskaya O, Plésiat P. 2003. MexXY-OprM efflux pump is necessary for adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 47: 1371–1375.
  • Hollingshead S, Vapnek D. 1985. Nucleotide sequence analysis of a gene encoding a streptomycin/spectinomycin adenylyltransferase. Plasmid 13: 17–30.
  • Humes HD, Weinberg JM, Knauss TC. 1982. Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am J Kidney Dis 2: 5–29.
  • Ikäheimo I, Syrjälä H, Karhukorpi J, Schildt R, Koskela M. 2000. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 46: 287–290.
  • Ioannidou E, Siempos II, Falagas ME. 2007. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: A meta-analysis. J Antimicrob Chemother 60: 1216–1226.
  • Islam S, Jalal S, Wretlind B. 2004. Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 10: 877–883.
  • Jackson J, Chen C, Buising K. 2013. Aminoglycosides: How should we use them in the 21st century? Curr Opin Infect Dis 26: 516–525.
  • Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M. 2014. Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis 78: 429–436.
  • Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 47: 1681–1688.
  • Kim C, Mobashery S. 2005. Phosphoryl transfer by aminoglycoside 3′-phosphotransferases and manifestation of antibiotic resistance. Bioorg Chem 33: 149–158.
  • Kislak JW. 1972. The susceptibility of Bacteroides fragilis to 24 antibiotics. J Infect Dis 125: 295–299.
  • Kotra LP, Haddad J, Mobashery S. 2000. Aminoglycosides: Perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 44: 3249–3256.
  • Landman D, Babu E, Shah N, Kelly P, Bäcker M, Bratu S, Quale J. 2010. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J Antimicrob Chemother 65: 2123–2127.
  • Landman D, Kelly P, Bäcker M, Babu E, Shah N, Bratu S, Quale J. 2011. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 66: 332–334.
  • Le J, McKee B, Srisupha-Olarn W, Burgess DS. 2011. In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae. J Clin Med Res 3: 106–110.
  • Le Goffic F, Baca B, Soussy CJ, Dublanchet A, Duval J. 1976. ANT(4′)I: A new aminoglycoside nucleotidyltransferase found in “staphylococcus aureus.” Ann Microbiol (Paris) 127: 391–399 (author’s transl.).
  • Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66: 48–53.
  • Llano-Sotelo B, Azucena EF, Kotra LP, Mobashery S, Chow CS. 2002. Aminoglycosides modified by resistance enzymes display diminished binding to the bacterial ribosomal aminoacyl-tRNA site. Chem Biol 9: 455–463.
  • Lode H, Grunert K, Koeppe P, Langmaack H. 1976. Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J Infect Dis 134: S316–S322.
  • Macinga DR, Rather PN. 1999. The chromosomal 2′-N-acetyltransferase of Providencia stuartii: Physiological functions and genetic regulation. Front Biosci 4: D132–D140.
  • Magnet S, Blanchard JS. 2005. Molecular insights into aminoglycoside action and resistance. Chem Rev 105: 477–498.
  • Magnet S, Courvalin P, Lambert T. 2001. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 45: 3375–3380.
  • Martin WJ, Gardner M, Washington JA. 1972. In vitro antimicrobial susceptibility of anaerobic bacteria isolated from clinical specimens. Antimicrob Agents Chemother 1: 148–158.
  • Matsumoto T. 2014. Arbekacin: Another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clin Pharmacol 6: 139–148.
  • Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. 1999. Aminoglycosides: Activity and resistance. Antimicrob Agents Chemother 43: 727–737.
  • Miró E, Grünbaum F, Gómez L, Rivera A, Mirelis B, Coll P, Navarro F. 2013. Characterization of aminoglycoside-modifying enzymes in enterobacteriaceae clinical strains and characterization of the plasmids implicated in their diffusion. Microb Drug Resist 19: 94–99.
  • Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. 1984. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100: 352–357.
  • Murphy E. 1985. Nucleotide sequence of a spectinomycin adenyltransferase AAD(9) determinant from Staphylococcus aureus and its relationship to AAD(3″)(9). Mol Gen Genet 200: 33–39.
  • Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ. 1999. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 19: 1252–1260.
  • Mushtaq S, Irfan S, Sarma JB, Doumith M, Pike R, Pitout J, Livermore DM, Woodford N. 2011. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother 66: 2002–2005.
  • Mwengee W, Butler T, Mgema S, Mhina G, Almasi Y, Bradley C, Formanik JB, Rochester CG. 2006. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis 42: 614–621.
  • Nagabhushan T, Miller G, Weinstein M. 1982. Structure–activity relationships in aminoglycoside-aminocyclitol antibiotics. In The aminoglycosides: Microbiology, clinical use and toxicology (ed. Whelton A, Neu HC), pp. 3–27. Marcel Dekker, New York.
  • Nichols WW, Young SN. 1985. Respiration-dependent uptake of dihydrostreptomycin by Escherichia coli. Its irreversible nature and lack of evidence for a uniport process. Biochem J 228: 505–512.
  • Nicolau DP, Belliveau PP, Nightingale CH, Quintiliani R, Freeman CD. 1995. Implementation of a once-daily aminoglycoside program in a large community-teaching hospital. Hosp Pharm 30: 674–676, 679–680.
  • Okamoto S, Suzuki Y. 1965. Chloramphenicol-, dihydrostreptomycin-, and kanamycin-inactivating enzymes from multiple drug-resistant Escherichia coli carrying episome “R”. Nature 208: 1301–1303.
  • Ounissi H, Derlot E, Carlier C, Courvalin P. 1990. Gene homogeneity for aminoglycoside-modifying enzymes in Gram-positive cocci. Antimicrob Agents Chemother 34: 2164–2168.
  • Pankuch GA, Seifert H, Appelbaum PC. 2010. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis 67: 191–197.
  • Plantinga NL, Bonten MJ. 2015. Selective decontamination and antibiotic resistance in ICUs. Crit Care 19: 259.
  • Podnecky NL, Rhodes KA, Schweizer HP. 2015. Efflux pump-mediated drug resistance in Burkholderia. Front Microbiol 6: 305.
  • Poirel L, Savov E, Nazli A, Trifonova A, Todorova I, Gergova I, Nordmann P. 2014. Outbreak caused by NDM-1- and RmtB-producing Escherichia coli in Bulgaria. Antimicrob Agents Chemother 58: 2472–2474.
  • Price R, MacLennan G, Glen J; SuDDICU Collaboration. 2014. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: Systematic review and network meta-analysis. BMJ 348: g2197.
  • Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P. 1993. Once versus thrice daily gentamicin in patients with serious infections. Lancet 341: 335–339.
  • Ramirez MS, Tolmasky ME. 2010. Aminoglycoside modifying enzymes. Drug Resist Updat 13: 151–171.
  • Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, et al. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340: 23–30.
  • Rather PN, Orosz E, Shaw KJ, Hare R, Miller G. 1993. Characterization and transcriptional regulation of the 2′-N-acetyltransferase gene from Providencia stuartii. J Bacteriol 175: 6492–6498.
  • Ristuccia AM, Cunha BA. 1985. An overview of amikacin. Ther Drug Monit 7: 12–25.
  • Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC. 2006. Fluoroquinolone-modifying enzyme: A new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12: 83–88.
  • Roos D, Dijksman LM, Tijssen JG, Gouma DJ, Gerhards MF, Oudemans-van Straaten HM. 2013. Systematic review of perioperative selective decontamination of the digestive tract in elective gastrointestinal surgery. Br J Surg 100: 1579–1588.
  • Rosenberg EY, Ma D, Nikaido H. 2000. AcrD of Escherichia coli is an aminoglycoside efflux pump. J Bacteriol 182: 1754–1756.
  • Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43: 1549–1555.
  • Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in U.S. and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012. Int J Antimicrob Agents 43: 328–334.
  • Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2015. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob Agents Chemother 59: 3263–3270.
  • Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L. 2012. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 47: 44–52.
  • Schwartz JJ, Gazumyan A, Schwartz I. 1992. rRNA gene organization in the Lyme disease spirochete, Borrelia burgdorferi. J Bacteriol 174: 3757–3765.
  • Shaw KJ, Rather PN, Hare RS, Miller GH. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57: 138–163.
  • Simon VK, Mösinger EU, Malerczy V. 1973. Pharmacokinetic studies of tobramycin and gentamicin. Antimicrob Agents Chemother 3: 445–450.
  • Skeggs PA, Thompson J, Cundliffe E. 1985. Methylation of 16S ribosomal RNA and resistance to aminoglycoside antibiotics in clones of Streptomyces lividans carrying DNA from Streptomyces tenjimariensis. Mol Gen Genet 200: 415–421.
  • Snowden J, Stovall S. 2011. Tularemia: Retrospective review of 10 years’ experience in Arkansas. Clin Pediatr (Phila) 50: 64–68.
  • Stover KR, Riche DM, Gandy CL, Henderson H. 2012. What would we do without metronidazole? Am J Med Sci 343: 316–319.
  • Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. 2009. Plasmid-mediated quinolone resistance: A multifaceted threat. Clin Microbiol Rev 22: 664–689.
  • Stubbings W, Bostock J, Ingham E, Chopra I. 2006. Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in Escherichia coli. J Antimicrob Chemother 58: 444–448.
  • Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 2571–2581.
  • Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, et al. 2011. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: An open-label, non-inferiority, randomised controlled trial. Lancet 377: 477–486.
  • Swenson JM, Wallace RJ, Silcox VA, Thornsberry C. 1985. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 28: 807–811.
  • Taber HW, Mueller JP, Miller PF, Arrow AS. 1987. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev 51: 439–457.
  • Tamma PD, Cosgrove SE, Maragakis LL. 2012. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25: 450–470.
  • Thompson J, Skeggs PA, Cundliffe E. 1985. Methylation of 16S ribosomal RNA and resistance to the aminoglycoside antibiotics gentamicin and kanamycin determined by DNA from the gentamicin-producer, Micromonospora purpurea. Mol Gen Genet 201: 168–173.
  • Vakulenko SB, Mobashery S. 2003. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 16: 430–450.
  • Wachino J, Arakawa Y. 2012. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: An update. Drug Resist Updat 15: 133–148.
  • Wachino J, Yamane K, Shibayama K, Kurokawa H, Shibata N, Suzuki S, Doi Y, Kimura K, Ike Y, Arakawa Y. 2006. Novel plasmid-mediated 16S rRNA methylase, RmtC, found in a Proteus mirabilis isolate demonstrating extraordinary high-level resistance against various aminoglycosides. Antimicrob Agents Chemother 50: 178–184.
  • Wachino J, Shibayama K, Kurokawa H, Kimura K, Yamane K, Suzuki S, Shibata N, Ike Y, Arakawa Y. 2007. Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob Agents Chemother 51: 4401–4409.
  • Waters VL. 1999. Conjugative transfer in the dissemination of β-lactam and aminoglycoside resistance. Front Biosci 4: D433–D456.
  • Westbrock-Wadman S, Sherman DR, Hickey MJ, Coulter SN, Zhu YQ, Warrener P, Nguyen LY, Shawar RM, Folger KR, Stover CK. 1999. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 43: 2975–2983.
  • Wilson DN. 2014. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol 12: 35–48.
  • World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. World Health Organization, Geneva.
  • Wright GD, Thompson PR. 1999. Aminoglycoside phosphotransferases: Proteins, structure, and mechanism. Front Biosci 4: D9–D21.
  • Yamane K, Wachino J, Doi Y, Kurokawa H, Arakawa Y. 2005. Global spread of multiple aminoglycoside resistance genes. Emerg Infect Dis 11: 951–953.
  • Yan JJ, Wu JJ, Ko WC, Tsai SH, Chuang CL, Wu HM, Lu YJ, Li JD. 2004. Plasmid-mediated 16S rRNA methylases conferring high-level aminoglycoside resistance in Escherichia coli and Klebsiella pneumoniae isolates from two Taiwanese hospitals. J Antimicrob Chemother 54: 1007–1012.
  • Yokoyama K, Doi Y, Yamane K, Kurokawa H, Shibata N, Shibayama K, Yagi T, Kato H, Arakawa Y. 2003. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 362: 1888–1893.
  • Zhanel GG, Hoban DJ, Harding GK. 1991. The postantibiotic effect: A review of in vitro and in vivo data. DICP 25: 153–163.

Aminoglycosides

. | Skip to navigation

  • Accessibility

There is a newer version of this site available at

Sections
  • Overview
    • Sitemap
    • Modules
    • Project Information
  • Pharmacology
    • Historical Perspectives
      • The Pre-Antibacterial Era
      • The Golden Age of Antibacterials
      • What Lies Beyond?
    • Antimicrobials
      • Antimicrobials: An Introduction
      • Spectrum of Activity
      • Effect on Bacteria
      • Mode of Action
      • Antibiotics of Veterinary Importance
        • Aminoglycosides
        • Beta Lactam Antibiotics
        • Chloramphenicol
        • Diaminopyrimidines (Trimethoprim)
        • Glycopeptides
        • Fluroquinolones
        • Polymixins
        • Lincosamides
        • Macrolides
        • Rifamycins
        • Streptogramins
        • Sulfonamides
        • Tetracyclines
    • Antimicrobial Usage in Animals
      • Therapeutic Use of Antibiotics
      • Non-Therapuetic use of Antimicrobials in Animals
        • Growth Promotion
        • Prophylactic or Metaphylactic Use
    • Summary
  • Microbiology
    • Antimicrobial Resistance
    • Bacterial Resistance Strategies
      • Introduction
        • Mechanisms of Resistance Against Different Antimicrobial Classes
      • Strategy 1: Preventing Access
      • Strategy 2: Use of Efflux Pumps
      • Strategy 3: Agent Modification
      • Strategy 4: Target Modification
    • Molecular Basis for Antimicrobial Resistance
      • Intrinsic Resistance
      • Acquired Resistance
        • Mutation
        • Horizontal Gene Transfer
    • Detecting Antimicrobial Resistance
      • Approaches and Strategies
      • Test Methods
        • Examples of Antibiotic Sensitivity Testing Methods
    • Module Key Points
    • References and Suggested Readings
  • Public Health
    • Veterinary Public Health
    • I. Introduction
      • Examples of Antimicrobials Important in Human Medicine Being Used for Animal Treatment, Metaphylaxis or Growth Promotion
      • Figure 2. Possible Spread of Antibiotic-Resistant Bacteria from Animals to Humans.
    • II. The Human Health Impact Of Antimicrobial Resistance In Animal Populations
      • A. Increased human morbidity
      • B. Increased human mortality
      • C. Reduced efficacy to related antibiotics used in human medicine
      • D. Increased human healthcare costs
      • E. Increased carriage and dissemination
      • F. Facilitated emergence of resistance in human pathogens
    • III. The environmental impact of imprudent antimicrobial use in animals
      • A. Veterinary antibiotics in soil
      • B. Veterinary antibiotics in water
      • C. Effects on other ecosystems
    • IV. The Global Health Impact Of Antimicrobial Resistance In Animal Populations
      • Veterinary-related Factors Influencing the Global Spread of AMR
      • National and International AMR Programs
    • References and Resources
    • Summary
  • Animated
    • Integrated Principals
      • 1. Purpose and Goals
      • 2. Introduction
      • 3. Mechanisms of resistance
      • 4. The public health officer
      • 5. Salmonella epidemiology
      • 6. Food History
      • 7. Small Animal Clinic
      • 8. The physical exam
      • 9. Simon the cat
      • 10. Horse exposure
      • 11. Farm biosecurity
      • 12. Use of antibiotics
      • 13. At the micro lab
      • 14. Selecting an antibiotic
      • 15. Empiric Therapy
      • 16. Pharmacology
      • 17. Using MIC values
      • 18. Case Wrap-up
      • 19. Antimicrobials and agriculture
      • 20. Salmonella resistance
        • Resistance: Animal to Human (2 of 2)
      • 21. Conclusion
      • 22. Epilog
      • Glossary
    • The Hunt for Ella Salmonella
    • The Hunt for Ella Salmonella Book II
    • Global Perspectives – The Danish Experiment:
  • Species Specific
    • Dairy Cattle
      • Medicated Milk Replacer
        • 1. Farm Background
        • 2. Farm Tour
        • 3. Medicated Milk Replacer
        • 4. Calf Management
        • 5. Medicated Milk Replacer
        • 6. MMR Frequency of Use
        • 7. Sanitation and hygiene
        • 8. Summary
        • 9. References
      • Neonatal Scours, Antibiotics and Dairy Calves
        • 1. Intro to Neonatal Scours, Antibiotics and Dairy Calves
        • 2. Farm Background
        • 3. Calf Management
        • 4. What next?
        • 5. Scours History
        • 6. Calf Records
        • 7. Farm Tour
        • 8. Physical Exam
        • 9. Diagnostic Specimens
        • 10. Necropsy
        • 11. Antibiotic Selection
        • 12. When to Use Antibiotics
        • 13. Fluid Administration
        • 14. Discussion with Client
        • 15. Colostrum Management
        • 16. Treatment plan
        • 17. Management Recommendations
        • 18. Laboratory Results
        • 19. Use of Antibiotics for Scours
        • 20. Summary
      • Model Mastitis Control Program
      • Contagious Mastitis Control in Dairy Cows
        • 1. Contagious Mastitis
        • 2. Contagious Mastitis
        • 3. Contagious Mastitis
        • 4. Contagious Mastitis
        • Contagious Mastitis 5
        • 6. Contagious Mastitis
        • 7. Contagious Mastitis
        • 8. Contagious Mastitis
        • 9. Contagious Mastitis
        • 10. Contagious Mastitis
        • 11. Contagious Mastitis
        • 12. Contagious Mastitis
        • 13. Contagious Mastitis
        • Cows to Culture
        • Cows to Culture
        • 14. Contagious Mastitis
        • 15. Mastitis Treatment and Prevention
        • 16. Summary
        • 17. References
    • Beef Cattle
      • Regression to the Mean and Antibiotic Efficacy
      • Antibiotics and Bovine Respiratory Disease:
        • 1. Introduction to Bovine Respiratory Disease (BRD)
        • 2. Cow-calf BRD
        • 3. Bovine Respiratory Disease Prevention
        • 4. Opportunistic Agents
        • 5. Preconditioning
        • 6. Preventing BRD
        • 7. Feedlot
        • 8. Diagnosis
        • 9. Treatment Protocols
        • 10. Management Summary
        • 11. Study questions
    • Pet Animals
      • Antimicrobial Use and Resistance In Companion Animal Medicine
        • 1. Introduction to Antimicrobial Use In Small Animals
        • 2. Scenario
        • 3. Antimicrobial use in small animal practice.
        • 4. Classes and types of antimicrobials used in small animal practice.
        • 5. Antimicrobial use and antimicrobial resistance.
        • 6. Improving antimicrobial use
        • 7. Wrap up
        • 8. Reference List
      • Rodent Multiple-Drug Resistant Salmonella Outbreak
        • 1. Index Case
        • 2. Initial Questions
        • 3. Interview
        • 4. Necropsy
        • 5. Rodent Salmonella Outbreak
        • 6. PFGE
        • 7. Control Questions
        • 8. Source Identification
        • 9. Control Measures
        • 10. Additional Cases
        • 11. Pocket Pet Industry
        • 12. Rodent Antibiotics
        • 13. Salmonella & Antibiotics
        • 14. Public Awareness
        • 15. Antibiotic Summary
        • 16. Traceback Diagram
        • 17. Conclusions
      • Canine Pyoderma Teaching Module
        • 2. Introduction
        • 3. Differential Diagnoses
        • 4. Physical Examination
        • 5. Diagnostic Tests
        • 6. More Diagnostic Testing
        • 7. Laboratory Findings
        • 8. Initial Treatment
        • 9. Choosing an Antibiotic
        • 10. Clinical Response to Treatment
        • 11. Culture and Susceptibility Testing
        • 12. Sensitivity Results and Summary
      • Antibiotic Use in Feline Urinary Tract Disease
        • 01 Introduction
        • 02 Questions to ask
        • 03 Physical examination
        • 04 Narrowing your differentials
        • 05 Diagnostic Tests
        • 06 Sample Collection
        • 07 Cystocentesis
        • 08 Sample problems
        • 09 Getting a sample
        • 10 Results
        • 11 Diagnosis
        • 12 What to do next?
        • 13 Culture
        • 14 Initial Treatment
        • 15 Culture Results
        • 16 Diagnosis
        • 17 How to proceed?
        • 18 Treatment Plan
        • 19 Update
        • 20 References
    • Equine
      • Equine Upper Respiratory Infections
        • 1. Talking with the Owner
        • 2. Physical Exam
        • 3. Treatment Record for Cowboy
        • 4. Rounds
    • Swine
      • Post-Weaning Scours in Pigs
        • 01 Setup
        • 02 Clinical Signs-Post Mortem Exam Results
        • 03 Clinical Diagnosis
        • 04 Immediate Therapy implemented
        • 05 VCPR-PQA
        • 06 Diagnostic submission
        • 07 Diagnostic results review
        • 08 Optional Reading and Resources
        • 09 Follow-up check on the farm’s clinical picture.
        • 10 Prevention plan created
        • 11 What will we do going forward and what would the result likely be?
        • 12 Additional Resources
  • Support
    • Credits
    • Suggestion Box
    • Module PDF Files
      • Medicated Milk Replacer
      • Microbiology
      • Pharmacology
      • Vet Public Health

Personal tools

  • Log in

Adverse Effects from Gentamicin and Other Aminoglycosides

Aminoglycosides are known to cause ototoxic damage, vestibulo-toxic impairments, nephrotoxicity (kidney damage), and encephalopathy. If you have been adversely affected by aminoglycosides you may want to participate in this survey.

Adverse Effects from Gentamicin and Other Aminoglycosides, Including Impact on Daily Living Activities

Aminoglycosides are a class of drugs that are particularly potent against gram-negative bacteria, but are known to have toxic effects on some patients. This class of drugs includes gentamicin, tobramycin, neomycin, streptomycin, amikacin, kanamycin, netilmicin, and paromomycin. The medication may be given orally, as eardrops, topically, and perhaps most effectively intravenously or intramuscularly. This class of medications are effective against other types of bacteria, but because of the potential toxic effects of these drugs, they are usually reserved for specific types of infections.

People who have been damaged by aminoglycosides, particularly gentamicin, often experience a multitude of symptoms, have difficulty being diagnosed, and must learn to adapt to permanent damage and resultant limitations. It is well known that these drugs have the potential to cause hearing loss, vestibular damage, vision problems, kidney damage (nephrotoxicity), and some research exists documenting problems with thinking (cognitive impairment) when the vestibular system is damaged. Of course, a person suffering from any health problem may also experience emotional struggles as they learn to adapt to permanent limitations.

The purpose of this study is to explore the day to day limitations reported by people who have had an adverse effect from gentamicin and other drugs in the aminoglycoside family. It incorporates questions from the World Health Organization’s Disability Schedule, along with a list of general impairments and limitations that have been developed by an online group of patients who reported their day to day struggles living without a sense of balance. Many vestibular researchers focus on dizziness or vertigo which is not always present with patients damaged by aminoglycosides. When the vestibular system is damaged, people can lose a sense of where their body is in space, which is known as proprioception. When other senses are impaired, such as in the dark, a person without a fully functioning vestibular system may fall. This study also explores other symptoms drawn from adverse-reporting sites for these drugs and also explores health conditions that arose after the administration of aminoglycosides in order to look for other common health issues in these patients.

If you have been adversely affected by aminoglycosides and would like to participate in this survey, please

Aminoglycosides are known to cause ototoxic damage, vestibulo-toxic impairments, nephrotoxicity (kidney damage), and encephalopathy. These four categories are discussed below.

Ototoxicity refers to damage usually caused by medications that damage the inner ear, including the cochlea, vestibule, semicircular canals and otoliths (1). The results of this toxic damage include hearing loss, tinnitus, dizziness, and balance impairment. Although the ototoxic results of aminoglycosides have been demonstrated, the exact mechanism of the damage they cause is still a subject of research. Sensory hair cells within the ear canal die, but the exact reason why this occurs and how it might be prevented are current topics of interest to researchers. (2)

The vestibular system itself is composed of the both peripheral and central vestibular components. The ear canals and the otolithic organs within the ear are constantly picking up sensory information and relaying it to the central vestibular system, which also receives information from our vision and proprioceptive input to let us retain balance as we walk and move (3). Damage can occur both to the peripheral vestibular system and the central vestibular system. The central vestibular system includes parts of the brain and brainstem that process information obtained from the peripheral vestibular system regarding balance and spatial orientation. Those with damage to the central vestibular system may not experience vertigo, but instead have more difficulty with balance and exhibit ataxia, which is the medical term for an abnormal gait when walking (3).

Aminoglycosides are also well known to cause nephrotoxicity (kidney damage) although this can usually be reversed. Methods of preventing such damage, which usually occurs when the medication is given intravenously, have not been completely successful in medical care (4). Currently, while giving gentamicin and/or a combination of aminoglycosides intravenously the patient’s creatinine levels are monitored to protect the kidneys. But this does not eliminate potential damage to susceptible patients. Exactly why certain patients are more susceptible to kidney damage is unclear. No dose of gentamycin is safe (5).

Encephalopathy is a term used to describe a malfunction in the brain caused by some other agent, such as a neurotoxin, infection, impaired liver function, or other condition. Several studies have indicated that gentamicin may be involved in its development. Post-mortem findings in a patient who was given intrathecal (through the spinal cord) administration of gentamicin included brain lesions in multiple areas and damage to myelin sheaths. The authors of that study were able to reproduce those findings using rabbits (6). In a more recent report, a woman was given an overdose of gentamicin and developed myoclonus (involuntary muscle jerks or spasms), which abated when the intravenous administration of gentamicin was discontinued (7). Many patients with vestibular disorders from gentamicin report problems with memory and cognitive functions, such as the inability to multi-task and concentrate (8). A case study on a 9 year old boy reported encephalopathy after treatment with gentamicin (9). Aminoglycosides are toxic not only to hair cells in the inner ear, but also to the ganglia around the eighth cranial nerve. This damage is not instantaneous but understood to be an ongoing process of cell damage (10). Medical staff often do not notice the symptoms that develop as a result of gentamicin dosing, especially if the patient is confined to the bed. Because many medical practitioners are unaware of the signs of ototoxic or vestibular damage, checking patients for hearing loss or balance disorders often does not occur. In an Australian retrospective study, 103 patients were interviewed. Of those, twenty-one patients first noted symptoms while still receiving treatment with gentamicin, and only one reported that treatment was halted after their complaints (11).

On eHealthMe, over 8000 reports of side effects from the administration of gentamicin were listed. Encephalopathy was not identified, but conditions such as multi-organ failure, hypoesthesia (partial loss of sensation), and death were reported (12). A similar variety of symptoms were reported for other aminoglycosides. The purpose of this study is to have patients with aminoglycoside-induced impairments to complete the World Health Organization Disability Assessment Schedule 2.0 along with a list of symptoms they experienced and health conditions that arose after administration of this class of drugs. It is hoped that a compilation of the severity of impairments and daily living limitations might be helpful information for those who are seeking care from medical providers and dealing with insurance companies. If you have been adversely affected by aminoglycosides and would like to participate, please click on the link below.

To participate in the research survey, .

Principal Investigator:

Name: Ann M. Kerlin, PhD

Assistant Professor of Counseling

Address: 3038 Evans Mill Road, Lithonia, GA 30038

Phone: 770-484-1204 ext. 5688

E-mail:

Sources Cited

AMINOGLYCOSIDES (Systemic)

Some commonly used brand names are:

In the U.S.—

  • Amikin 1
  • Garamycin 2
  • G-Mycin 2
  • Jenamicin 2
  • Kantrex 3
  • Nebcin 7
  • Netromycin 5

In Canada—

  • Amikin 1
  • Garamycin 2
  • Nebcin 7
  • Netromycin 5

Note:

For quick reference, the following aminoglycosides are numbered to match the corresponding brand names.

Category

  • Antibacterial, antimycobacterial—Streptomycin
  • Antibacterial, systemic—Amikacin; Gentamicin; Kanamycin; Netilmicin; Streptomycin; Tobramycin

Description

Aminoglycosides (a-mee-noe-GLYE-koe-sides) are used to treat serious bacterial infections. They work by killing bacteria or preventing their growth.

Aminoglycosides are given by injection to treat serious bacterial infections in many different parts of the body. In addition, some aminoglycosides may be given by irrigation (applying a solution of the medicine to the skin or mucous membranes or washing out a body cavity) or by inhalation into the lungs. Streptomycin may also be given for tuberculosis (TB). These medicines may be given with 1 or more other medicines for bacterial infections, or they may be given alone. Aminoglycosides may also be used for other conditions as determined by your doctor. However, aminoglycosides will not work for colds, flu, or other virus infections.

Aminoglycosides given by injection are usually used for serious bacterial infections for which other medicines may not work. However, aminoglycosides may also cause some serious side effects, including damage to your hearing, sense of balance, and kidneys. These side effects may be more likely to occur in elderly patients and newborn infants. You and your doctor should talk about the good these medicines may do as well as the risks of receiving them .

Aminoglycosides are to be administered only by or under the immediate supervision of your doctor. They are available in the following dosage forms:

  • Irrigation
  • Kanamycin
    • Irrigation solution (U.S.)

Before Receiving This Medicine

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For aminoglycosides, the following should be considered:

Allergies—Tell your doctor if you have ever had any unusual or allergic reaction to any of the aminoglycosides. Also tell your health care professional if you are allergic to any other substances, such as foods, sulfites, or other preservatives.

Pregnancy—Studies on most of the aminoglycosides have not been done in pregnant women. Some reports have shown that aminoglycosides, especially streptomycin and tobramycin, may cause damage to the infant’s hearing, sense of balance, and kidneys if the mother was receiving the medicine during pregnancy. However, this medicine may be needed in serious diseases or other situations that threaten the mother’s life. Be sure you have discussed this with your doctor.

Breast-feeding—Aminoglycosides pass into breast milk in small amounts. However, they are not absorbed very much when taken by mouth. To date, aminoglycosides have not been reported to cause problems in nursing babies.

Children—Children are especially sensitive to the effects of aminoglycosides. Damage to hearing, sense of balance, and kidneys is more likely to occur in premature infants and neonates.

Older adults—Elderly people are especially sensitive to the effects of aminoglycosides. Serious side effects, such as damage to hearing, sense of balance, and kidneys may occur in elderly patients.

Other medicines—Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving aminoglycosides it is especially important that your health care professional knows if you are taking any of the following:

Other medical problems—The presence of other medical problems may affect the use of the aminoglycosides. Make sure you tell your doctor if you have any other medical problems, especially:

  • Kidney disease—Patients with kidney disease may have increased aminoglycoside blood levels and increased chance of side effects
  • Loss of hearing and/or balance (eighth-cranial-nerve disease)—High aminoglycoside blood levels may cause hearing loss or balance disturbances
  • Myasthenia gravis or
  • Parkinson’s disease—Aminoglycosides may cause muscular problems, resulting in further muscle weakness

Proper Use of This Medicine

To help clear up your infection completely, aminoglycosides must be given for the full time of treatment , even if you begin to feel better after a few days. Also, this medicine works best when there is a certain amount in the blood or urine. To help keep the correct level, aminoglycosides must be given on a regular schedule.

Dosing—The dose of aminoglycosides will be different for different patients. Follow your doctor’s orders or the directions on the label . The following information includes only the average doses of aminoglycosides. Your dose may be different if you have kidney disease. If your dose is different, do not change it unless your doctor tells you to do so.

The dose of most aminoglycosides is based on body weight and must be determined by your doctor. The medicine is injected into a muscle or vein. Depending on the aminoglycoside prescribed, doses are given at different times and for different lengths of time. These times are as follows:

  • For amikacin
  • For all dosage forms:
    • Adults and children: The dose is given every eight or twelve hours for seven to ten days.
    • Newborn babies: The dose is given every twelve hours for seven to ten days.
    • Premature babies: The dose is given every eighteen to twenty-four hours for seven to ten days.
  • For gentamicin
  • For all dosage forms:
    • Adults and children: The dose is given every eight hours for seven to ten days or more.
    • Infants: The dose is given every eight to sixteen hours for seven to ten days or more.
    • Premature and full-term newborn babies: The dose is given every twelve to twenty-four hours for seven to ten days or more.
  • For kanamicin
  • For all dosage forms:
    • Adults and children: The dose is given every eight or twelve hours for seven to ten days.
  • For netilmicin
  • For all dosage forms:
    • Adults and children: The dose is given every eight or twelve hours for seven to fourteen days.
  • For streptomycin
  • For all dosage forms—The dose of streptomycin is often not based on body weight and the amount given depends on the disease being treated.
    • Treatment of tuberculosis (TB) :
      • Adults: Dose is based on body weight and must be determined by your doctor. This dose is injected into a muscle. The dosing schedule will also be determined by your doctor, usually once daily or twice weekly or three times-a-week. This medicine must be given with other medicines for tuberculosis (TB).
      • Children and adolescents: Dose is based on body weight and must be determined by your doctor. This dose is injected into a muscle. The dosing schedule will also be determined by your doctor, usually once daily or twice weekly or three times-a-week. This medicine must be given with other medicines for tuberculosis (TB).
    • Treatment of bacterial infections :
      • Adults: 250 to 500 milligrams of streptomycin is injected into a muscle every six hours; or 500 milligrams to 1 gram of streptomycin is injected into a muscle every twelve hours.
      • Children and adolescents: Dose is based on body weight and must be determined by your doctor. This dose is injected into a muscle every six to twelve hours.
  • For tobramycin
  • For all dosage forms:
    • Adults and adolescents: The dose is given every six to eight hours for seven to ten days or more.
    • Older infants and children: The dose is given every six to sixteen hours.
    • Premature and full-term newborn babies: The dose is given every twelve to twenty-four hours.

Side Effects of This Medicine

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your health care professional immediately if any of the following side effects occur:

More common

Any loss of hearing; clumsiness or unsteadiness; dizziness; greatly increased or decreased frequency of urination or amount of urine; increased thirst; loss of appetite; nausea or vomiting; numbness, tingling, or burning of face or mouth (streptomycin only); muscle twitching, or convulsions (seizures); ringing or buzzing or a feeling of fullness in the ears

Less common

Any loss of vision (streptomycin only); skin rash, itching, redness, or swelling

Rare—Once-daily or “high dose” gentamicin only-

Shaking; chills; fever

Difficulty in breathing; drowsiness; weakness

In addition, leg cramps, skin rash, fever, and convulsions (seizures) may occur when gentamicin is given by injection into the muscle or a vein, and into the spinal fluid.

For up to several weeks after you stop receiving this medicine, it may still cause some side effects that need medical attention. Check with your doctor if you notice any of the following side effects or if they get worse:

Any loss of hearing; clumsiness or unsteadiness; dizziness; greatly increased or decreased frequency of urination or amount of urine; increased thirst; loss of appetite; nausea or vomiting; ringing or buzzing or a feeling of fullness in the ears

Other side effects not listed above may also occur in some patients. If you notice any other effects, check with your doctor.

Revised: 09/11/2002

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *